title: Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
abstract: Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.
authors.affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
authors.forename: Liping
authors.initials: L
authors.lastname: Dai
authors.affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
authors.forename: Jitian
authors.identifier: 0000-0001-9857-3226
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
authors.forename: Rosalia
authors.initials: R
authors.lastname: Ortega
authors.affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
authors.forename: Wei
authors.identifier: 0000-0002-9563-721X
authors.initials: W
authors.lastname: Qian
authors.affiliation: Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Casiano
authors.affiliation: Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood*; D015551:Autoimmunity; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D016022:Case-Control Studies; D056744:Cyclin B1 / Q000037:antagonists & inhibitors / Q000097:blood* / Q000276:immunology; D042241:Early Diagnosis; D015870:Gene Expression; D006801:Humans; D008297:Male; D000090243:Nucleophosmin; D017430:Prostate-Specific Antigen / Q000097:blood / Q000235:genetics; D011470:Prostatic Hyperplasia / Q000097:blood / Q000276:immunology; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; C534699:CCNB1 protein, human; D056744:Cyclin B1; C000716967:NPM1 protein, human; D000090243:Nucleophosmin; D017430:Prostate-Specific Antigen